Anti-Aging$65–$125

NAD+: Dosage, Benefits & Side Effects

By Peptide Assistant Editorial Team · · · 11 sources cited

Overview

NAD+ (nicotinamide adenine dinucleotide) is a critical coenzyme found in every living cell that plays essential roles in energy metabolism, DNA repair, gene expression regulation, and cellular signaling. NAD+ levels have been reported to decline with age in human skin and brain and in mouse organs, and this decline is implicated in numerous age-related diseases; a 2026 study of seven human cohorts, however, found whole-blood NAD+ stable with age. Supplementation via IV infusion, subcutaneous injection, or precursors aims to restore youthful NAD+ levels and support cellular function.

Mechanism of Action

NAD+ serves as the primary electron carrier in mitochondrial oxidative phosphorylation, shuttling electrons through Complexes I–IV of the electron transport chain to drive ATP synthesis. Beyond energy production, NAD+ is the essential substrate for three families of enzymes critical to aging and health: sirtuins (SIRT1-7), which deacetylate proteins to regulate gene expression, mitochondrial function, and stress responses; PARPs (poly-ADP-ribose polymerases), which consume NAD+ to repair DNA damage; and CD38/CD157, ectoenzymes involved in immune cell signaling. As NAD+ declines with age, competition between these enzyme families intensifies — PARP activity increases due to accumulated DNA damage, depleting the NAD+ pool and reducing sirtuin activity. This creates a vicious cycle of declining mitochondrial function, impaired DNA repair, and accelerated aging. Exogenous NAD+ supplementation aims to break this cycle by restoring the available pool.

NAD+ Benefits: What the Research Shows

  • Yoshino et al. (2011) in Cell Metabolism demonstrated NMN (NAD+ precursor) restored NAD+ levels and improved glucose tolerance in aged mice
  • A 2013 study by Gomes et al. in Cell showed that raising NAD+ levels in aged mice with the precursor NMN for one week restored mitochondrial function to youthful parameters
  • Rajman et al. (2018) published a comprehensive review in Cell Metabolism summarizing NAD+ decline as a hallmark of aging with therapeutic potential
  • A 2019 pilot study (Grant et al.) infused 750 mg of NAD+ IV over 6 hours in 8 healthy men and found it was cleared from plasma for at least the first 2 hours; it did not test cognition or fatigue, and no controlled trial of IV NAD+ for those outcomes has been published
  • Camacho-Pereira et al. (2016) in Cell Metabolism identified CD38 as the primary NAD+-consuming enzyme driving age-related NAD+ decline
  • Preclinical studies show that raising NAD+ with the precursor nicotinamide riboside improves mitochondrial and stem cell function and extends life span in aged mice

NAD+ Dosage

  • IV infusion: 250–500 mg over 2–4 hours, 1–2 times per week (clinical setting)
  • Subcutaneous injection: 50–200 mg daily or every other day
  • Intramuscular injection: 100–200 mg 2–3 times per week
  • NAD+ precursors (oral): NMN 250–1000 mg/day or NR 300–600 mg/day as alternatives
  • Loading protocol: daily injections or IV infusions for 1–2 weeks, then transition to maintenance
  • IV infusions should be administered slowly — rapid infusion can cause chest pressure, nausea, and flushing
  • Cycle: continuous use is common for anti-aging protocols, with periodic bloodwork to monitor NAD+ levels
NAD+ dosage calculator: get your dose in syringe units →

Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.

NAD+ Side Effects & Safety

Known Side Effects

  • Nausea and abdominal discomfort — common during IV infusion, mitigated by slower infusion rates
  • Chest tightness or pressure — reported during rapid IV infusion; resolves by slowing the rate
  • Injection site pain — subcutaneous NAD+ injections can cause a burning sensation due to the compound's acidity
  • Flushing and warmth — transient vasodilation during or after administration
  • Headache — occasionally reported, usually mild and self-resolving
  • Insomnia — if administered late in the day due to increased cellular energy production

Safety Profile

NAD+ is an endogenous molecule essential for life, and supplementation has a strong theoretical safety basis. IV NAD+ infusion is offered in clinics, including for addiction and chronic fatigue, but the published human evidence is limited to small uncontrolled studies and case reports, and long-term safety data are lacking. The primary risks relate to administration route — IV infusion can cause moderate to severe gastrointestinal symptoms, chest pressure and a raised heart rate, which resolved once the infusion ended in the one comparative study. Subcutaneous injections are often described as better tolerated, but no published human study has evaluated them. There are no known dangerous drug interactions, though individuals on chemotherapy should consult their oncologist, as NAD+ could theoretically support DNA repair in cancer cells. Long-term safety data are lacking. Quality and purity of injectable NAD+ products vary significantly between suppliers.

What to Expect

Day 1 (IV): Immediate energy boost reported by many users within hours of infusion. Improved mental clarity and reduced brain fog. Some users describe a 'switched on' feeling. Week 1: Consistent improvements in energy, focus, and exercise recovery. Sleep quality often improves. Mood elevation is commonly reported. Weeks 2–4: Cumulative benefits become more pronounced — improved exercise endurance, faster recovery, clearer skin, and sustained mental clarity. Some users notice improvements in chronic fatigue or age-related sluggishness. Months 1–3: Long-term users report sustained vitality improvements. Bloodwork may show improved metabolic markers. The anti-aging benefits are best understood as cumulative and preventive rather than dramatic or acute.

Common Stacks

Storage & Handling

Store NAD+ solution refrigerated at 2–8°C. Most injectable NAD+ products have a shelf life of 6–12 months when properly refrigerated. Do not freeze. NAD+ in solution can degrade if exposed to heat or light. Lyophilized NAD+ powder can be stored at -20°C for extended periods. Verify the pH of injectable solutions (should be approximately 7.0–7.4 for IV use). Protect from light and store in amber vials when possible.

Pricing & Available Variants

$65 – $125price range
500mg1000mg

Prices sourced from peptides.gg marketplace. Prices may vary.

References

  1. Alangari A, Arif J, Al Qureshah F, et al. Narrative review of intravenous NAD(+) and NAD(+) precursors in wellness and translational medicine. Front Aging. 2026.
  2. Grant R, Berg J, Mestayer R, et al. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD. Front Aging Neurosci. 2019.
  3. Reyna K, Heinzen G, Patel N, et al. Intravenous infusion of nicotinamide adenine dinucleotide (NAD(+)) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Front Aging. 2026.
  4. Massudi H, Grant R, Braidy N, et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One. 2012.
  5. Zhu XH, Lu M, Lee BY, et al. In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences. Proc Natl Acad Sci U S A. 2015.
  6. Trętowicz MM, Scantlebery AML, Schomakers BV, et al. Human whole-blood NAD(+) levels do not vary with age or lifestyle interventions. Nat Metab. 2026.
  7. Rajman L, Chwalek K, Sinclair DA. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metab. 2018.
  8. Yoshino J, Mills KF, Yoon MJ, et al. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011.
  9. Gomes AP, Price NL, Ling AJ, et al. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013.
  10. Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metab. 2016.
  11. Zhang H, Ryu D, Wu Y, et al. NAD⁺ repletion improves mitochondrial and stem cell function and enhances life span in mice. Science. 2016.

Related Peptides

Track NAD+ in Your Protocol

Log your NAD+ doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.

Start Tracking Free